[Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology].

[Update on endocrine orbitopathy]. Ophthalmologe (2013) 0.78

[Graves' ophthalmopathy from the internist's perspective]. Ophthalmologe (2011) 0.76

[Graves' ophthalmopathy]. Ophthalmologe (2016) 0.75

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82

Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol (2010) 3.93

Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45

Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J (2002) 3.35

Selenium and the course of mild Graves' orbitopathy. N Engl J Med (2011) 3.06

Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot (2006) 3.03

Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol (2008) 2.70

Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging (2009) 2.67

Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65

Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet (2012) 2.43

Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery (2006) 2.35

Residence close to high traffic and prevalence of coronary heart disease. Eur Heart J (2006) 2.34

Running: the risk of coronary events : Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners. Eur Heart J (2008) 2.28

Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23

Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy. Ophthalmology (2011) 2.23

Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med (2007) 2.14

Fine Needle Aspiration in the Investigation of Thyroid Nodules. Dtsch Arztebl Int (2016) 2.13

Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol (2011) 2.03

I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab (2011) 2.02

False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97

Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab (2006) 1.92

Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91

Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90

Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol (2010) 1.86

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86

Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid (2014) 1.81

Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab (2003) 1.74

Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72

Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod (2006) 1.71

Value of plasma fibrin D-dimers for detection of acute aortic dissection. J Am Coll Cardiol (2004) 1.70

Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging (2003) 1.68

Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers. Environ Health Perspect (2009) 1.68

Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J Nucl Med (2005) 1.63

Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years. Ann Surg (2007) 1.62

Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61

Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol (2007) 1.59

Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg (2008) 1.58

Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol (2007) 1.58

Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America. Atherosclerosis (2007) 1.58

Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57

Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 1.56

Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta (2008) 1.56

Posterior retroperitoneoscopic adrenalectomy for clinical and subclinical Cushing's syndrome. World J Surg (2010) 1.55

Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med (2012) 1.53

Cardiovascular risk factors and signs of subclinical atherosclerosis in the Heinz Nixdorf Recall Study. Dtsch Arztebl Int (2008) 1.52

To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51

¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging (2012) 1.50

Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol (2013) 1.50

Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49

Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48

Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab (2012) 1.47

Left ventricular volumes and mass in marathon runners and their association with cardiovascular risk factors. Int J Cardiovasc Imaging (2008) 1.47

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45

Segmentation of PET volumes by iterative image thresholding. J Nucl Med (2007) 1.43

Proteomics of tear fluid in thyroid-associated orbitopathy. Thyroid (2012) 1.43

Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg (2006) 1.42

MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging (2008) 1.42

Solid supported multicomponent lipid membranes studied by x-ray spectromicroscopy. Biointerphases (2008) 1.42

Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging (2009) 1.41

Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38

Medication safety in a psychiatric hospital. Gen Hosp Psychiatry (2007) 1.37

Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol (2005) 1.36

Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol (2004) 1.31

Prognostic value of preoperative cardiac troponin I in patients undergoing emergency coronary artery bypass surgery with non-ST-elevation or ST-elevation acute coronary syndromes. Circulation (2006) 1.30

Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29

Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol (2003) 1.29

Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med (2008) 1.28

Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol (2010) 1.28

Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27

Ferro- and Antiferromagnetic Coupling through 1,n-Dithiosquarate Bridges (n = 2, 3) in Copper(II) Dimers. Syntheses, Crystal Structures, and Magnetic Properties of [Cu(2)(bpca)(2)(1,2-dtsq)(H(2)O)].2H(2)O and [Cu(2)(bpca)(2)(1,3-dtsq)].2H(2)O. Inorg Chem (1999) 1.21

Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab (2009) 1.20

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood (2008) 1.20

Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol (2013) 1.19

No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2009) 1.18

Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging (2010) 1.17

Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis (2007) 1.16

Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med (2008) 1.15

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer (2005) 1.15

Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res (2006) 1.14

Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study. Atherosclerosis (2013) 1.14

The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. Neuroimage (2004) 1.14

Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14

Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid (2005) 1.13

Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13

Smoking cessation and subclinical atherosclerosis--results from the Heinz Nixdorf Recall Study. Atherosclerosis (2008) 1.13

Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias. World J Surg (2004) 1.12

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J (2016) 1.11

Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab (2002) 1.10

Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol (2006) 1.09

Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab (2009) 1.09

IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol (2008) 1.09

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg (2010) 1.09

Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg (2002) 1.08